HARROW, INC. (HROW)
D
Pipeline Grade
Financial Position (from SEC Filings)
$72.6M
Cash & Equivalents
$9.0M
Quarterly Burn Rate
24 mo
Est. Cash Runway
$1,583M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (3)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT07456826 | Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5... | PHASE4 | Enrolling By Invitation | 236 |
| NCT07566975 | Real-World Assessment of VEVYE® for Short-Term Symptom and Sign Improvement of Dry Eye Disease in a Neuro-Ophthalmology... | OTHER | Recruiting | 50 |
| NCT07224529 | Efficacy of Vevye Ophthalmic Solution for the Treatment of Meibomian Gland Dysfunction | PHASE4 | Recruiting | 48 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.